Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide in Children With Autism Spectrum Disorder
NCT07005414Phase 2Completed
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bumetanide in Autism Spectrum Disorder (ASD) (2 arms). Primary endpoint: Social Responsiveness Scale, Second Edition at 3 months. Started Jun 2025; status: completed.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07005414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005414.